Updated time: 2022-04-22 08:54:07
28A-1080424
2021-02-23
TW I759888 PCT patents pending.
In this work, we smartly applied our privileged and unique small molecule library, previously developed by a natural product-inspired combinatorial chemistry approach, to perform the acid α-glucosidase enzyme stabilization evaluation. Unexpectedly, we found some small molecules sharing with the almost same configuration pattern as hits for our protein stabilization purpose. After systematic modifications and bio-evaluations, advanced compounds were developed to selectively stabilize the lysosomal acid α-glucosidase in enzyme or cell-based studies. In addition, our data showed that this compound can stabilize an exogeneous acid α-glucosidase enzyme during drug delivery toward Pompe cell lines. Potentially, the compound can reduce the usage of protein drugs in enzyme replacement therapy toward the Pompe treatment.
- Easy preparation and no toxic effect.
- Better results and activities than current known ones in cell-based studies.
- This small molecule can stabilizer the current protein drug to cost down of current enzyme replacement therapy toward Pompe disease.
- For the treatment of Pompe disease, one of lysosomal storage diseases.
- Selective small molecules can stabilize acid α-glucosidase enzyme.
Wei-Chieh Cheng, Huang-Yi Li, Wuh-Liang Hwu, Yin-Hsiu Chien, Ni-Chung Lee
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Small molecules as protein stabilizers for the treatment of Pompe disease